XML 55 R39.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Segments    
Compensation and benefits, excluding stock-based compensation $ 3,027 $ 2,239
Stock-based compensation 2,650 1,251
Drug manufacturing 431 1,830
Clinical trial 5,043 1,927
Outside general and administrative 1,244 946
Facilities and insurance 558 780
Other segment items 1,924 949
Total segment expense 14,877 9,922
Non-operating income, net (1,185) (25,115)
Net loss $ 13,692 $ (15,193)
Number of operating segments 1 1